Merus (MRUS) Aktie Kurs

Merus NV is primarily active in the biotechnology industry.

The main competitors of Merus NV in the market include biotechnology companies such as Regeneron Pharmaceuticals, Inc., Amgen Inc., Genmab A/S, and Roche Holding AG. These companies operate in similar therapeutic areas, developing innovative antibody-based therapeutics and immuno-oncology treatments, potentially competing with Merus NV's pipeline. It is important for investors and market participants to closely monitor the competitive landscape as it can impact Merus NV's market share, product development, and financial performance.

Merus NV is a biotechnology company based in the Netherlands. Founded in 2003, the company specializes in developing innovative bispecific antibody therapeutics for the treatment of cancer. Merus NV has a unique approach to target tumor cells directly while minimizing side effects. The company has a strong pipeline of candidates, including MCLA-128, MCLA-117, and MCLA-158, targeting various types of cancers. With collaborations and partnerships with renowned pharmaceutical companies, Merus NV aims to advance the field of antibody therapeutics and make a lasting impact on patient care. Throughout its history, Merus NV has achieved significant milestones in drug discovery and clinical development, positioning itself as a key player in the biotechnology industry.

Merus NV, a leading biotechnology company, has achieved several significant milestones. The company successfully initiated multiple clinical trials, including ongoing studies for its innovative bispecific antibody programs. Merus NV also secured strategic collaborations with renowned pharmaceutical companies, further validating its cutting-edge technology and expanding its market reach. In addition, Merus NV has received regulatory approvals for its investigational therapies, paving the way for potential commercialization. These achievements demonstrate the company's strong commitment to advancing its pipeline and driving growth. Merus NV's dedication to scientific excellence and continuous innovation positions it as a formidable player in the biotech industry.

Merus NV is primarily present in the Netherlands and the United States.

Merus NV represents values such as innovation, collaboration, and patient-centricity. With a commitment to advancing bispecific antibody therapeutics, Merus NV aims to improve patient outcomes and address unmet medical needs. The company's corporate philosophy is based on fostering scientific excellence and leveraging its core technologies to develop transformative medicines. Merus NV embraces a culture of integrity, diversity, and teamwork, driving its pursuit of novel solutions in the field of oncology. By integrating its unique approach with strategic partnerships, Merus NV strives to deliver breakthrough treatments for patients.

Analytikere sætter i øjeblikket et gennemsnitligt kursmål på 99,48 USD for Merus-aktien (median: 98,94 USD), svarende til +10,5 % i forhold til seneste kurs. Konsensus bygger på 23 analytikervurderinger.

Merus Analytikerens Kursmål 2026

23 analytikere vurderer i øjeblikket Merus-aktien: 9 anbefaler køb, 14 hold og 0 salg. For 2026 forventer analytikere, at Merus genererer omsætning på 49,33 Mio. USD og indtjening pr. aktie på -5,44 USD.

Merus Analytikerens Kursmål 2026

Omregnet til den aktuelle valutakurs handles Merus-aktien til 80,75 EUR (90,00 USD).

Merus-aktien (MRUS) er noteret på 3 børser, herunder: NASDAQ (MRUS), Frankfurt (2GH.F), München (2GH.MU).

Merus NV is a biotechnology company specializing in the development of bispecific antibodies for the treatment of cancer. The company's business model is based on the research, development, and commercialization of novel therapies to combat cancer. Merus NV has three main business areas and develops products in each of these categories: therapeutic products, diagnostics, and research. The company's therapeutic products utilize bispecific antibodies (Biclonics®) that combine the properties of two different antibodies, resulting in greater specificity, higher efficacy, and reduced toxicity. Merus NV is building a pipeline of bispecific antibodies targeting a variety of cancer types. Currently, the company has three products in clinical development: MeMo, MCLA-128, and MCLA-117. Merus NV collaborates closely with renowned pharmaceutical companies such as Incyte and DSM Biomedical in the development of cancer immunotherapies. In the diagnostics product line, Merus NV offers a technology platform that enables the development of diagnostic tests for therapeutic products and supports biomarker research. The company is also involved in the development of antibody imaging tools, serving an important role in toxic analysis and biomarker-driven clinical studies. Finally, Merus NV's research department supports its own development activities as well as those of external parties through collaborations and alliances. In summary, Merus NV's business model is based on the development, commercialization, and marketing of bispecific antibodies to combat cancer. With innovative solutions and technologies in the field of diagnostic tests and therapy monitoring, the company has distinct competitive advantages and can meet the demands of customers and partners. Merus NV is a leading company in the field of bispecific antibody technology and offers a diverse product pipeline to meet the demanding requirements of the entire cancer market.

forventet-omsætningen for Merus er 49,33 Mio. USD. Dette tal er baseret på aktuelle finansielle data og afspejler virksomhedens forretningsydeevne.

forventet-overskuddet for Merus er -374,11 Mio. USD. Nettooverskuddet afspejler virksomhedens rentabilitet efter fradrag af alle udgifter.

Pris-til-indtjening-forholdet (P/E) for Merus er i øjeblikket -16,56. P/E-forholdet sammenligner den nuværende aktiekurs med indtjeningen pr. aktie og hjælper investorer med at vurdere værdiansættelsen af Merus-aktien.

Pris-til-salgs-forholdet (P/S) for Merus er i øjeblikket 125,58. P/S-forholdet sammenligner markedskapitalisering med årlig omsætning og fungerer som en værdiansættelsesmetrik for Merus-aktien.

AlleAktien-kvalitetsscore for Merus er 3/10.

ISIN for Merus er NL0011606264. ISIN (International Securities Identification Number) er en globalt unik identifikator for værdipapirer.

WKN for Merus er A2AKFX. WKN (Wertpapierkennnummer) er et seks-cifret tysk identifikationsnummer for værdipapirer.

Tickeren for Merus er MRUS. Tickersymbolet bruges til at handle Merus-aktier på børsen.